The progress in precision medicine, with Epidermal Growth Factor Receptor (EGFR) inhibitors, Anaplastic Lymphoma Kinase (ALK) inhibitors, and immune checkpoint inhibitors, has significantly improved survival and quality of life for patients with advanced lung cancer [24,33]. The gene discussed is ALK; the disease is lung carcinoma.